深南電路(002916.SZ):上半年研發投入佔營收比重6.24% 同比提升0.49個百分點
格隆匯11月16日丨深南電路(002916.SZ)在投資者互動平台回覆表示,公司長期堅持技術領先戰略,持續加大研發投入規模,2023年上半年,公司研發投入佔營收比重6.24%,同比提升0.49個百分點。公司在總部、事業部和生產廠層面分別下設研發部、產品研發部和技術部,形成三級研發體系,根據公司每年經營計劃制定相應的研發目標和計劃。公司重視人才的選育用留,多年來培育出了一支開拓創新、團結進取的研發隊伍,主要成員深耕行業多年,具備專業的行業領域知識與經驗、具有良好的職業素養。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.